To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Zymework spurns All Blue Capital’s $773m takeover bid
Zymeworks' board of directors has rejected an unsolicited, non-binding acquisition offer from an affiliate of UK-based All Blue Capital.
